Cooperative Agreement R01FD003713

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $472,124 to Beth Israel Deaconess Medical Center, Inc. to conduct exploratory studies on the role of TREM1 and TREM2 receptors in the immune response to glioblastoma, an aggressive form of brain cancer. The research aims to use a novel mouse model of glioblastoma to investigate how...

This Project Grant from the National Institutes of Health's National Cancer Institute totaling $668,151 will support the development of highly multiplexed live-cell G protein-coupled receptor (GPCR) arrays for glioma drug discovery. Spectragenetics, Inc. will deploy an automated multiplexed live-cell assay to detect and quantify agonist and inverse-agonist activities against 55 GPCRs known to be upregulated or downregulated in human gliomas. The assay will be used to screen 48 established...

This federal Project Grant award from the U.S. Department of Health and Human Services' National Cancer Institute provides $547,519 to Oregon Health & Science University (OHSU) to leverage biologically-specific PET/MRI monitoring and therapeutic modulation of the hypoxic glioblastoma tumor immune microenvironment (TIME) in order to improve outcomes for patients with glioblastoma, an aggressive form of brain cancer. The key objectives are to: 1) Define a biologically-specific imaging...

This Project Grant award, with a total funding amount of $553,167.00, was provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The Washington University in Illinois, USA. The grant supports a Phase 1/2 clinical trial to evaluate the safety and efficacy of combining a peptide vaccine (PEP-CMV) targeting cytomegalovirus (CMV) antigens with the checkpoint inhibitor nivolumab for the treatment of newly diagnosed and recurrent pediatric brain tumors, including...

Federal Project Grant Award Summary Cleveland Clinic Lerner College of Medicine of Case Western Reserve University received a $638,697 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective July 15, 2025, through June 30, 2030. The award supports research investigating the role of SMARCA5, an ISWI (Imitation Switch/Chromatin Remodeling)...

Federal Grant Award Summary The National Institute of Neurological Disorders and Stroke (NINDS) awarded a Project Grant totaling $429,000 to the University of Michigan's Office of Research and Sponsored Projects, effective August 1, 2025, through July 31, 2027, under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853). The research project investigates the mechanism of Notch inhibition resistance in glioblastoma (GBM) stem cells to develop novel...

Federal Cooperative Agreement Summary Brigham & Women's Hospital Inc. received a $790,474 Cooperative Agreement award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), effective April 1, 2026, through March 31, 2028. The award supports development of MIRTED, a precision medicine therapeutic based on lipid nanoparticle (LNP) delivery of CRISPR/Cas9 gene...

Federal Project Grant Award Summary Round Table Research, Inc., in collaboration with researchers at UNC-Chapel Hill, received a $305,031 Phase I Small Business Technology Transfer (STTR) award from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), effective September 1, 2025 through August 31, 2026. The project advances engineered extracellular vesicle (EV) therapy for glioblastoma (GBM), the most aggressive form of brain cancer. The award supports the...

This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $430,375 over 2 years (9/1/2024 - 8/31/2026) to the Mayo Clinic Jacksonville (a nonprofit organization) to explore the role of extracellular vesicles in mediating communication between glioblastoma (GBM) cells and the tumor microenvironment, specifically within the subventricular...

Federal Project Grant Award Summary Massachusetts General Hospital, operating under The General Hospital Corporation, received a $707,798 Project Grant award from the National Cancer Institute (NCI) effective April 1, 2026, through March 31, 2031, under the Cancer Biology Research program (CFDA 93.396). The award supports fundamental research to identify mechanisms underlying heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor characterized by rapid recurrence and...